First Time Loading...
Y

Yili Chuanning Biotechnology Co Ltd
SZSE:301301

Watchlist Manager
Yili Chuanning Biotechnology Co Ltd
SZSE:301301
Watchlist
Price: 13.18 CNY 20.04% Market Closed
Updated: May 3, 2024
Section:
 

Wall Street
Price Targets

Price Targets Summary
Yili Chuanning Biotechnology Co Ltd

Wall Street analysts forecast Yili Chuanning Biotechnology Co Ltd stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Yili Chuanning Biotechnology Co Ltd is 10.61 CNY with a low forecast of 10.5 CNY and a high forecast of 10.92 CNY.

Lowest Forecast
Wall Street Target
10.5 CNY
20% Downside
Average Forecast
Wall Street Target
10.61 CNY
20% Downside
Highest Forecast
Wall Street Target
10.92 CNY
17% Downside
Lowest
Price Target
10.5 CNY
20% Downside
Average
Price Target
10.61 CNY
20% Downside
Highest
Price Target
10.92 CNY
17% Downside
Yili Chuanning Biotechnology Co Ltd Competitors:
Price Targets
I
086890
Isu Abxis Co Ltd
122% Upside
B
251120
Bio-FD&C Co Ltd
36% Upside
HARP
Harpoon Therapeutics Inc
8% Upside
PHM
Pharma Mar SA
71% Upside
I
086890
Isu Abxis Co Ltd
122% Upside
B
251120
Bio-FD&C Co Ltd
36% Upside
HARP
Harpoon Therapeutics Inc
8% Upside
PHM
Pharma Mar SA
71% Upside
ABIO
ARCA Biopharma Inc
115% Upside
VYGR
Voyager Therapeutics Inc
113% Upside
T
TSBX
Turnstone Biologics Corp
408% Upside
APLT
Applied Therapeutics Inc
161% Upside

Revenue
Forecast

Revenue Estimate
Yili Chuanning Biotechnology Co Ltd

For the last 1 year the compound annual growth rate for Yili Chuanning Biotechnology Co Ltd's revenue is 18%. The projected CAGR for the next 3 years is 15%.

18%
Past Growth
15%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Yili Chuanning Biotechnology Co Ltd

For the last 1 year the compound annual growth rate for Yili Chuanning Biotechnology Co Ltd's operating income is 69%. The projected CAGR for the next 3 years is 11%.

69%
Past Growth
11%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Yili Chuanning Biotechnology Co Ltd

For the last 1 year the compound annual growth rate for Yili Chuanning Biotechnology Co Ltd's net income is 270%. The projected CAGR for the next 3 years is 38%.

270%
Past Growth
38%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Yili Chuanning Biotechnology Co Ltd's stock price target?
Price Target
10.61 CNY

According to Wall Street analysts, the average 1-year price target for Yili Chuanning Biotechnology Co Ltd is 10.61 CNY with a low forecast of 10.5 CNY and a high forecast of 10.92 CNY.

What is Yili Chuanning Biotechnology Co Ltd's Revenue forecast?
Projected CAGR
15%

For the last 1 year the compound annual growth rate for Yili Chuanning Biotechnology Co Ltd's revenue is 18%. The projected CAGR for the next 3 years is 15%.

What is Yili Chuanning Biotechnology Co Ltd's Operating Income forecast?
Projected CAGR
11%

For the last 1 year the compound annual growth rate for Yili Chuanning Biotechnology Co Ltd's operating income is 69%. The projected CAGR for the next 3 years is 11%.

What is Yili Chuanning Biotechnology Co Ltd's Net Income forecast?
Projected CAGR
38%

For the last 1 year the compound annual growth rate for Yili Chuanning Biotechnology Co Ltd's net income is 270%. The projected CAGR for the next 3 years is 38%.

ALPHA SPREAD
Join more than 133,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.